When the immune system has become your enemy

A unique treatment for introducing immunological tolerance

Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues.

Link to: Idogen´s technologyLink to: Stock informationLink to: Upcoming eventsLink to: Presentations and Interviews

Idogen´s technology enables development of tolerogenic cell therapy in a number of areas

Read more about our therapeutic areas:

Idogen develops tolerogenic cell therapy

Individualised treatment for each patient


Which information would you like to subscribe to?
Which information would you like to subscribe to?


BioStock-intervju med VD Anders Karlsson om om listbytet, status i bolagets utvecklingsprojekt samt vad som väntar härnäst

Se intervjun här:

VD Anders Karlsson kommenterar listningen på Nasdaq First North och de senaste händelserna i bolaget.

Se Redeye-intervjun här: https://www.redeye.se/research/786562/idogen-intervju-med-vd-anders-karlsson-video-5

Load More...

Idogen AB   |   Medicon Village   |   Scheelevägen 2   |   SE-223 81 Lund   |  Sweden   |  E-mail: info at idogen dot com

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.